[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100497934":3},{"organization":4,"armGroups":7,"interventions":18,"overallOfficials":25,"centralContacts":29,"locations":40,"responsibleParty":59,"collaborators":24,"id":61,"slug":62,"hasResults":63,"nctId":64,"briefTitle":65,"officialTitle":66,"acronym":67,"eligibilityCriteria":68,"healthyVolunteers":63,"sex":69,"minAge":70,"maxAge":24,"enrollmentInfo":71,"targetDuration":24,"studyType":74,"phases":75,"briefSummary":77,"conditions":78,"keywords":80,"overallStatus":42,"whyStopped":24,"lastUpdateSubmitDate":82,"lastUpdatePostDateStruct":83,"startDateStruct":86,"completionDateStruct":88,"leadSponsor":90,"locationsCount":91},{"fullName":5,"class":6},"Jessa Hospital","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Experimental: PBM1 group","EXPERIMENTAL","The patients allocated to the first PBM-group will receive twelve PBM sessions of 6 J\u002Fcm² over six weeks (2x\u002Fweek).",[13],"Device: Multiwave Locked System® (M6 laser, ASA srl, Arcugnano (VI), Italy)",{"label":15,"type":10,"description":16,"interventionNames":17},"Experimental: PBM2 group","The patients allocated to the second PBM-group will receive twelve PBM sessions of 8 J\u002Fcm² over six weeks (2x\u002Fweek).",[13],[19],{"type":20,"name":21,"description":22,"armGroupLabels":23,"otherNames":24},"DEVICE","Multiwave Locked System® (M6 laser, ASA srl, Arcugnano (VI), Italy)","MLS® Laser M6 is a PBM device that allows the patients to be treated in various positions, either sitting, lying down or at a distance, without risk of contamination. Treatment times are carefully calibrated to deliver the best possible energy dose to the tissue being treated.",[9,15],null,[26],{"name":27,"affiliation":5,"role":28},"Jeroen mebis, Prof. Dr.","PRINCIPAL_INVESTIGATOR",[30,36],{"name":31,"role":32,"phone":33,"phoneExt":34,"email":35},"Jeroen Mebis, Prof. Dr.","CONTACT","011 33 72 21","+32","jeroen.mebis@jessazh.be",{"name":37,"role":32,"phone":38,"phoneExt":34,"email":39},"Marithé Claes, MSc","011 33 72 39","marithe.claes@uhasselt.be",[41],{"facility":5,"status":42,"city":43,"state":44,"zip":45,"country":46,"countryCode":47,"cosmosGeoPoint":48,"geoPoint":53,"contacts":54},"RECRUITING","Hasselt","Limburg","3500","Belgium","BE",{"type":49,"coordinates":50},"Point",[51,52],5.33781,50.93106,{"lat":52,"lon":51},[55,57],{"name":31,"role":32,"phone":56,"phoneExt":24,"email":35},"+32 11 33 72 21",{"name":37,"role":32,"phone":58,"phoneExt":24,"email":39},"+32 11 33 72 39",{"type":60,"investigatorFullName":24,"investigatorTitle":24,"investigatorAffiliation":24,"oldNameTitle":24,"oldOrganization":24},"SPONSOR","100497934","photobiomodulation-therapy-in-the-management-of-chemotherapy-induced-peripheral-neuropathy-100497934",false,"NCT05763706","Photobiomodulation Therapy in the Management of Chemotherapy-Induced Peripheral Neuropathy","Evaluating the Efficacy of Photobiomodulation Therapy in the Management of Chemotherapy-induced Peripheral Neuropathy: a Randomized Controlled Trial","NeuroLight 2","Inclusion Criteria:\n\n* Finished one of the following types of chemotherapy: paclitaxel, docetaxel, oxaliplatin, cisplatin, vincristine, thalidomide and\u002For bortezomib.\n* Diagnosed with CIPN\n* Age 18 years or above\n* Have no documented or observable psychiatric or neurological disorders that might interfere with study participation (e.g., dementia or psychosis)\n* Dutch-speaking\n* Signed informed consent\n\nExclusion Criteria:\n\n* Taking stable doses of medication on prescription for peripheral neuropathy. Related medications are: gabapentin, pregabalin (Lyrica), nortriptyline, amitriptyline, duloxetine (Cymbalta), and venlafaxine.\n* Severe or unstable cardio- respiratory or musculoskeletal disease\n* Interruption of more than two consecutive laser treatments\n* Dark brown or black skin pigmentation (described as skin type VI in the Fitzpatrick scale)","ALL","18 Years",{"count":72,"type":73},172,"ESTIMATED","INTERVENTIONAL",[76],"NA","This study aims to investigate the effectiveness of photobiomodulation therapy (PBM) in the management of chemotherapy-induced peripheral neuropathy (CIPN). Therefore, the hypothesis is that PBM can reduce the severity of CIPN in cancer patients, increasing the patient's quality of life.",[79],"Chemotherapy-induced Peripheral Neuropathy",[81],"Photobiomodulation therapy","2023-03-28",{"date":84,"type":85},"2023-03-30","ACTUAL",{"date":87,"type":85},"2023-03-27",{"date":89,"type":73},"2030-03-15",{"name":5,"class":6},1]